Chest Physician, Department of Medicine, Vora Clinic, Mumbai, Maharashtra, India, Corresponding Author.
Consultant Cardiologist, Department of Cardiology, Holy Spirit Hospital, Mumbai, Maharashtra, India.
J Assoc Physicians India. 2024 Sep;72(9S):38-39. doi: 10.59556/japi.72.0677.
Pulmonary edema, either cardiogenic or noncardiogenic, is caused by fluid accumulation in the alveolar spaces. Cardiogenic pulmonary edema (CPE), one of the causes of congestive heart failure (CHF), is treated with loop diuretics. Torsemide and furosemide were found to be useful in the treatment of CHF-associated pulmonary edema due to their ability to lower pulmonary capillary pressure and left ventricular end-diastolic pressure, respectively. Pharmacological features of torsemide, such as greater bioavailability, higher absorption rate, and efficacy, make it a better alternative for treating pulmonary edema than the regularly used loop diuretic, furosemide. Torsemide administered intravenously was found to be both efficacious and well tolerated in CPE. However, more research is needed to determine its usefulness in non-CPE.
肺水肿，无论是心源性还是非心源性，是由肺泡腔内液体积聚引起的。心源性肺水肿（CPE）是充血性心力衰竭（CHF）的原因之一，用袢利尿剂治疗。托塞米和呋塞米因其能够降低肺毛细血管压和左心室舒张末期压而被发现对 CHF 相关肺水肿的治疗有用。托塞米的药理学特性，如更高的生物利用度、更高的吸收率和疗效，使其成为治疗肺水肿的更好选择，而不是常规使用的袢利尿剂，呋塞米。静脉给予托塞米被发现对 CPE 既有效又耐受良好。然而，还需要更多的研究来确定它在非 CPE 中的有用性。
